A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention

PharmacoEconomics

Volumn 32, Issue 4, 2014, Pages 377-393

  Hatz, Maximilian H M ^a,b   Leidl, Reiner ^b,c   Yates, Nichola A ^b   Stollenwerk, Björn ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; CEREBROVASCULAR ACCIDENT; CHECKLIST; COMPARATIVE STUDY; COST UTILITY ANALYSIS; DECISION TREE; HEALTH ECONOMICS; HUMAN; MEDICAL DECISION MAKING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TOTAL QUALITY MANAGEMENT; DECISION MAKING; ECONOMICS; PROBABILITY; PROCEDURES; STATISTICAL MODEL;

ACUTE CORONARY SYNDROME; DECISION MAKING; DECISION TREES; FIBRINOLYTIC AGENTS; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84897564611     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0128-4     Document Type: Review

References (76)

1. Hamm CW, Arntz HR, Bode C, Giannitsis E, Katus H, Levenson B, et al. Akutes Koronarsyndrom (ACS). 2005. http://leitlinien.dgk.org/files/2005-Pocket- Leitlinien-Akutes-Koronarsyndrom.pdf. Accessed 7 March 2013.
2. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31(20):2501-55.
3. Ryan J, Cohen DJ. Are drug-eluting stents cost-effective? It depends on whom you ask. Circulation. 2006;114(16):1736-43 (discussion 1744).
4. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999-3054.
5. Hoekstra J, Cohen M, Giugliano R, Granger CB, Gurbel PA, Hollander JE, et al. Expert consensus on treatment strategies in non-ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention - an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective: report on a roundtable discussion. Am J Emerg Med. 2009;27(6):720-8.
6. Maxwell CB, Holdford DA, Crouch MA, Patel DA. Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes. Ann Pharmacother. 2009;43(4):586-95.
7. Palmer S, Sculpher M, Philips Z, Robinson M, Ginnelly L, Bakhai A, et al. Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service? Int J Cardiol. 2005;100(2):229-40.
8. Schwenkglenks M, Toward TJ, Plent S, Szucs TD, Blackman DJ, Baumbach A. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. Heart. 2012;98(7):544-51.
9. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddard GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press Inc.; 2005.
10. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. 1st ed. New York: Oxford University Press Inc.; 2006.
11. Caro JJ, Briggs AH, Siebert U, Kuntz KM, Force I-SMGRPT. Modeling good research practices - overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force - 1. Value Health. 2012;15(6):796-803.
12. Hoch JS, Smith MW. A guide to economic evaluation: methods for cost-effectiveness analysis of person-level data. J Trauma Stress. 2006;19(6):787-97.
13. Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ. 2011;342:d1766.
14. AMCP, ISPOR, NCP. Comparative Effectiveness Research-Collaborative Initiative, advancing appropriate use of comparative evidence to improve patient health outcomes. http://www.ispor.org/TaskForces/InterpretingModelingStudiesTF. asp. Accessed 11 Sept 2013.
15. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics. 2013;31(5):361-7.
16. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8(36):iii-iv, ix-xi, 1-158.
17. Scatena R. Bivalirudin: a new generation antithrombotic drug. Exp Opin Invest Drugs. 2000;9(5):1119-27.
18. Chatterjee S, Ghose A, Sharma A, Guha G, Mukherjee D, Frankel R. Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events - evidence from a network meta-analysis. J Thromb Thrombolysis. 2012;36(3):223-32.
19. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355-71.
20. Langer A. A framework for assessing Health Economic Evaluation (HEE) quality appraisal instruments. BMC Health Serv Res. 2012;12:253.
21. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011. http://handbook.cochrane.org/. Accessed 12 Sept 2013.
22. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices - overview: a report of the ISPOR-SMDM modeling good research practices task force - 1. Med Decis Making. 2012;32(5):667-77.
23. Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force - 2. Med Decis Making. 2012;32(5):678-89.
24. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force - 3. Med Decis Making. 2012;32(5):690-700.
25. Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Moller J. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force - 4. Med Decis Making. 2012;32(5):701-11.
26. Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group - 5. Med Decis Making. 2012;32(5):712-21.
27. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group - 6. Med Decis Making. 2012;32(5):722-32.
28. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force - 7. Med Decis Making. 2012;32(5):733-43.
29. Summers KM, Holdford DA, Crouch MA. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention. Pharmacotherapy. 2006;26(5):609-18.
30. Karnon J, Bakhai A, Brennan A, Pandor A, Flather M, Warren E, et al. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. Int J Cardiol. 2006;109(3):307-16.
31. Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess. 2004;8(40):iii-iv, xv-xvi, 1-141.
32. Schwenkglenks M, Brazier JE, Szucs TD, Fox KA. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value Health. 2011;14(1):24-33.
33. Glaser R, Glick HA, Herrmann HC, Kimmel SE. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis. J Am Coll Cardiol. 2006;47(3):529-37.
34. Sculpher MJ, Lozano-Ortega G, Sambrook J, Palmer S, Ormanidhi O, Bakhai A, et al. Fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. Am Heart J. 2009;157(5):845-52.
35. Orlewska E, Budaj A, Tereszkowski-Kaminski D. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective. Pharmacoeconomics. 2003;21(10):737-48.
36. Latour-Perez J, de-Miguel-Balsa E. Cost effectiveness of fondaparinux in non-ST-elevation acute coronary syndrome. Pharmacoeconomics. 2009;27(7):585-95.
37. Latour-Perez J, de Miguel Balsa E, Betegon L, Badia X. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis. Value Health. 2008;11(5):853-61.
38. Amin AP, Marso SP, Rao SV, Messenger J, Chan PS, House J, et al. Cost-effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding. Circ Cardiovasc Qual Outcomes. 2010;3(4):358-65.
39. Dewilde S, Bruggenjurgen B, Nienaber C, Senges J, Welte R, Willich SN. Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany. Eur J Health Econ. 2012;13(4):381-91.
40. Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33(20):2569-619.
41. Mauskopf JA, Graham JB, Bae JP, Ramaswamy K, Zagar AJ, Magnuson EA, et al. Cost-effectiveness of prasugrel in a US managed care population. J Med Econ. 2012;15(1):166-74.
42. Borg S, Persson U, Allikmets K, Ericsson K. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model. Clin Ther. 2006;28(11):1947-59.
43. Reese ES, Daniel Mullins C, Beitelshees AL, Onukwugha E. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy. 2012;32(4):323-32.
44. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377(9784):2193-204.
45. Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol. 2009;53(22):2019-27.
46. Berg J, Fidan D, Lindgren P. Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials. Curr Med Res Opin. 2008;24(7):2089-101.
47. Lindgren P, Stenestrand U, Malmberg K, Jonsson B. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin Ther. 2005;27(1):100-10.
48. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med. 2005;142(4):251-9.
49. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force - 7. Value Health. 2012;15(6):843-50.
50. Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost. 2006;32(8):803-9.
51. Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res. 2006;118(2):165-76.
52. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28(13):1598-660.
53. Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol. 2004;44(9):1792-800.
54. Shin HW, Yoon HJ, Choi SW, Bae HJ, Sohn JH, Lee HM, et al. Acute stent thrombosis and heparin induced thrombocytopenia in a patient with ST-segment elevation myocardial infarction. Korean Circ J. 2012;42(9):646-9.
55. Shenoy C, Harjai KJ. Thrombocytopenia following percutaneous coronary intervention. J Interv Cardiol. 2011;24(1):15-26.
56. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J. 2000;140(2):206-11.
57. Viswanathan G, Kidambi A, Nelson A, Mayurathan G, Hardy J, Kesteven P, et al. Glycoprotein IIb/IIIa inhibitor associated severe thrombocytopenia in patients with coronary artery disease: clinical course and outcomes. Platelets. 2012;23(3):224-8.
58. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502-7.
59. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes I, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464-76.
60. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464-76.
61. Ben-Gal Y, Moses JW, Mehran R, Lansky AJ, Weisz G, Nikolsky E, et al. Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. JACC Cardiovasc Interv. 2010;3(10):1059-67.
62. Smith EE, Cannon CP, Murphy S, Feske SK, Schwamm LH. Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndrome-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J. 2006;151(2):338-44.
63. Panattoni L, Brown PM, Te Ao B, Webster M, Gladding P. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation. Pharmacoeconomics. 2012;30(11):1067-84.
64. Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force - 2. Value Health. 2012;15(6):804-11.
65. Hawkins N, Sculpher M, Epstein D. Cost-effectiveness analysis of treatments for chronic disease: using R to incorporate time dependency of treatment response. Med Decis Making. 2005;25(5):511-9.
66. Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technol Assess. 1999;3(10):1-152.
67. Schulz S, Mehilli J, Ndrepepa G, Neumann FJ, Birkmeier KA, Kufner S, et al. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J. 2010;31(5):582-7.
68. Ndrepepa G, Schulz S, Keta D, Mehilli J, Birkmeier A, Massberg S, et al. Bleeding after percutaneous coronary intervention with bivalirudin or unfractionated heparin and one-year mortality. Am J Cardiol. 2010;105(2):163-7.
69. White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, et al. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2008;52(10):807-14.
70. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774-82.
71. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force - 3. Value Health. 2012;15(6):812-20.
72. Latimer NR. Survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743-54.
73. Zethraeus N, Molin T, Henriksson P, Jonsson B. Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med. 1999;246(2):151-9.
74. Schweikert B, Hahmann H, Leidl R. Validation of the EuroQol questionnaire in cardiac rehabilitation. Heart. 2006;92(1):62-7.
75. Ellis JJ, Eagle KA, Kline-Rogers EM, Erickson SR. Validation of the EQ-5D in patients with a history of acute coronary syndrome. Curr Med Res Opin. 2005;21(8):1209-16.
76. Becker C, Langer A, Leidl R. The quality of three decision-analytic diabetes models: a systematic health economic assessment. Expert Rev Pharmacoecon Outcomes Res. 2011;11(6):751-62.